Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 3/2010

01-03-2010 | Breast Oncology

Predictive Factors of Response to Decongestive Therapy in Patients with Breast-Cancer-Related Lymphedema

Authors: Isabel Forner-Cordero, MD, PhD, José Muñoz-Langa, MD, PhD, Arturo Forner-Cordero, PhD, Juan M. DeMiguel-Jimeno, MD

Published in: Annals of Surgical Oncology | Issue 3/2010

Login to get access

Abstract

Background

Many studies have reported the benefits of Decongestive treatment in patients with breast-cancer-related lymphedema (BCRL) but few have study what are the predictive factors of response.

Methods

We performed a prospective, multicenter controlled cohort study of 171 patients with BCRL to identify independent predictive factors of response to decongestive treatment (CDT). Demographic data and clinical and lymphedema characteristics were collected prospectively. The end point was the “percentage reduction in excess volume (PREV).” Volumes were measured prior and at the end of CDT. Factors associated with response (PREV) were tested in univariate and multivariate analyses using linear regression techniques.

Results

Median age was 60.4 years (range 32–84); mean lymphedema chronicity 4 years [95% confidence interval (95% CI): 3.1–5.0]; mean baseline excess volume (EV) was 936 mL (95% CI: 846–1026), and mean percentage EV was 35.3% (95% CI: 32.0–38.7); compliance to bandages was good in 81.3% of patients. PREV was 71.7% (95% CI: 65.2–78.2). After univariate screening, 11 variables were found to be associated with PREV but only 4 variables were independent predictive factors of response to CDT in the multivariate analysis: Venous insufficiency, percentage of EV (the higher the EV, the lower the reduction with CDT); compliance to bandages (a good compliance improved PREV in 25%), and treatment in autumn (better results than during the rest of the year).

Conclusions

This study shows that compliance to bandages during CDT is one of the most important predictors of response. Moreover, data support the idea that more severe lymphedemas have a worse response to treatment, and it should be recommended in early stages. The association between the season of treatment and response was also very strong, so weather conditions are an additional factor that must be taken into account in further studies.
Literature
1.
Földi E, Földi M. Lymphostatic diseases. In: Földi M, editors. Textbook of lymphology for physicians and lymphedema therapists. Munich: Urban & Fisher; 2003. p. 231–319.
2.
Ji RC. Lymphatic endothelial cells, lymphedematous lymphangiogenesis, and molecular control of edema formation. Lymphat Res Biol. 2008;6:123–37.CrossRefPubMed
3.
4.
Hinrichs CS, Watroba NL, Rezaishiraz H, Giese W, Hurd T, Fassl KA, et al. Lymphedema secondary to postmastectomy radiation: incidence and risk factors. Ann Surg Oncol. 2004;11:573–8.CrossRefPubMed
5.
Shih YC, Xu Y, Cormier JN, Giordano S, Ridner SH, Buchholz TA, et al. Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. J Clin Oncol. 2009;27:2007–14.CrossRefPubMed
6.
Norman SA, Localio AR, Potashnik SL, Simoes Torpey HA, Kallan MJ, et al. Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms. J Clin Oncol. 2009;27:390–7.CrossRefPubMed
7.
Hayes SC, Janda M, Cornish B, Battistutta D, Newman B. Lymphedema after breast cancer: incidence, risk factors, and effect on upper body function. J Clin Oncol. 2008;26:3536–42.CrossRefPubMed
8.
Paskett ED, Naughton MJ, McCoy TP, Case LD, Abbott JM. The epidemiology of arm and hand swelling in premenopausal breast cancer survivors. Cancer Epidemiol Biomarkers Prev. 2007;16:775–82.CrossRefPubMed
9.
Yen TW, Fan X, Sparapani R, Laud PW, Walker AP, Nattinger AB. A contemporary, population-based study of lymphedema risk factors in older women with breast cancer. Ann Surg Oncol. 2009;16:979–88.CrossRefPubMed
10.
Lee TS, Kilbreath SL, Refshauge KM, Herbert RD, Beith JM. Prognosis of the upper limb following surgery and radiation for breast cancer. Breast Cancer Res Treat. 2008;110:19–37.CrossRefPubMed
11.
12.
Ahmed RL, Prizment A, Lazovich D, Schmitz KH, Folsom AR. Lymphedema and quality of life in breast cancer survivors: the Iowa Women’s Health Study. J Clin Oncol. 2008;26:5689–96.CrossRefPubMed
13.
Kwan W, Jackson J, Weir LM, Dingee C, McGregor G, Olivotto IA. Chronic arm morbidity after curative breast cancer treatment: prevalence and impact on quality of life. J Clin Oncol. 2002;20:4242–8.CrossRefPubMed
14.
McWayne J, Heiney SP. Psychologic and social sequelae of secondary lymphedema: a review. Cancer. 2005;104:457–66.CrossRefPubMed
15.
Pain SJ, Vowler SL, Purushotham AD. Is physical function a more appropriate measure than volume excess in the assessment of breast cancer-related lymphoedema (BCRL)? Eur J Cancer. 2003;39:2168–72.CrossRefPubMed
16.
Paskett ED. Breast cancer-related lymphedema: attention to a significant problem resulting from cancer diagnosis. J Clin Oncol. 2008;26:5666–7.CrossRefPubMed
17.
International Society of Lymphology. The diagnosis and treatment of peripheral lymphedema. 2009 Consensus document of the International Society of Lymphology. Lymphology. 2009;42:51–60.
18.
Badger C, Preston N, Seers K, Mortimer P. Physical therapies for reducing and controlling lymphoedema of the limbs. Cochrane Database Syst Rev. 2004;Oct 18;:CD003141.
19.
Lawenda BD, Mondry TE, Johnstone PA. Lymphedema: a primer on the identification and management of a chronic condition in oncologic treatment. CA Cancer J Clin. 2009;59:8–24.CrossRefPubMed
20.
Erickson VS, Pearson ML, Ganz PA, Adams J, Kahn KL. Arm edema in breast cancer patients. J Natl Cancer Inst. 2001;93:96–111.CrossRefPubMed
21.
Ko DS, Lerner R, Klose G, Cosimi AB. Effective treatment of lymphedema of the extremities. Arch Surg. 1998;133:452–8.CrossRefPubMed
22.
Yamamoto R, Yamamoto T. Effectiveness of the treatment-phase of two-phase complex decongestive physiotherapy for the treatment of extremity lymphedema. Int J Clin Oncol. 2007;12:463–8.CrossRefPubMed
23.
Bertelli G, Venturini M, Forno G, Macchiavello F, Dini D. An analysis of prognostic factors in response to conservative treatment of postmastectomy lymphedema. Surg Gynecol Obstet. 1992;175:455–60.PubMed
24.
Forner-Cordero I, Muñoz-Langa J, DeMiguel-Jimeno JM, Rel-Monzo P. Physical therapies in the treatment of lymphedema: preliminary results of a phase III, multicenter, randomized, double-blind, controlled study. Abstracts of the XXXIV ESL congress, June 25–27, Naples, Italy. Eur J Lymphol Relat Probl. 2008;19:6.
25.
Ramos SM, O’Donnell LS, Knight G. Edema volume, not timing, is the key to success in lymphedema treatment. Am J Surg. 1999;178:311–5.CrossRefPubMed
26.
Vignes S, Porcher R, Champagne A, Dupuy A. Predictive factors of response to intensive decongestive physiotherapy in upper limb lymphedema after breast cancer treatment: a cohort study. Breast Cancer Res Treat. 2006;98:1–6.CrossRefPubMed
27.
Kurz I. Textbook of Dr. Vodder’s manual lymph drainage. In: Harris RS, eds. Therapy. 2nd ed. Heidelberg (Germany): Karl S. Haug Publishers; 1989.
28.
Chen YW, Tsai HJ, Hung HC, Tsauo JY. Reliability study of measurements for lymphedema in breast cancer patients. Am J Phys Med Rehabil. 2008;87:33–8.CrossRefPubMed
29.
Deltombe T, Jamart J, Recloux S, Legrand C, Vandenbroeck N, Theys S, et al. Reliability and limits of agreement of circumferential, water displacement, and optoelectronic volumetry in the measurement of upper limb lymphedema. Lymphology. 2007;40:26–34.PubMed
30.
George SL. Identification and assessment of prognostic factors. Semin Oncol. 1988;15:462–71.PubMed
31.
Lyman GH. Risk assessment in oncology clinical practice. From risk factors to risk models. Oncology. 2003;17:8–13.PubMed
32.
Kleinbaum DG. Logistic regression. A self-Learning text. New York: Springer-Verlag; 1994.
33.
Badger CM, Peacock JL, Mortimer PS. A randomized, controlled, parallel-group clinical trial comparing multilayer bandaging followed by hosiery versus hosiery alone in the treatment of patients with lymphedema of the limb. Cancer. 2000;88:2832–37.CrossRefPubMed
34.
Johansson K, Albertsson M, Ingvar C, Ekdahl C. Effects of compression bandaging with or without manual lymph drainage treatment in patients with postoperative arm lymphedema. Lymphology. 1999;32:103–10.PubMed
35.
McNeely ML, Magee DJ, Lees AW, Bagnall KM, Haykowsky M, Hanson J. The addition of manual lymph drainage to compression therapy for breast cancer related lymphedema: a randomized controlled trial. Breast Cancer Res Treat. 2004;86:95–106.CrossRefPubMed
36.
Clark M. Compression bandages: principles and definitions. In: European wound management association. Understanding compression therapy. London: Medical Education Partnership Ltd, 2003; 5–7.
37.
Partsch H. Understanding the pathophysiological effects of compression. In: European wound management association. Understanding compression therapy. London: Medical Education Partnership Ltd; 2003. p. 2–4.
38.
Kligman L, Wong RK, Johnston M, Laetsch NS. The treatment of lymphedema related to breast cancer: a systematic review and evidence summary. Support Care Cancer. 2004;12:421–31.CrossRefPubMed
39.
Lymphoedema Framework. Best practice for the management of lymphoedema. International Consensus. London: MEP Ltd; 2006.
40.
Moseley AL, Carati CJ, Piller NB. A systematic review of common conservative therapies for arm lymphoedema secondary to breast cancer treatment. Ann Oncol. 2007;18:639–46.CrossRefPubMed
41.
Forner-Cordero I, Muñoz-Langa J, Albiach-Gascó L, Maldonado-Garrido D. Efficacy of garments in the long-term management of post-mastectomy lymphedema: preliminary results from prospective cohort study. Eur J Lymphol Relat Probl. 2007;17:7–11.
42.
Shaw C, Mortimer P, Judd PA. Randomized controlled trial comparing a low-fat diet with a weight-reduction diet in breast cancer-related lymphedema. Cancer. 2007;109:1949–56.CrossRefPubMed
43.
Bergan JJ, Sparks S, Angle N. A comparison of compression pumps in the treatment of lymphedema. Vasc Endovascular Surg. 1998;32:455–62.CrossRef
44.
Forner-Cordero I, Navarro-Monsoliu R, Muñoz-Langa J, Rel-Monzó P. Early or late diagnosis of lymphedema in our Lymphedema Unit. Eur J Lymphol Relat Probl. 2006;16:19–23.
45.
Bar Ad V, Cheville A, Solin LJ, Dutta P, Both S, Harris EER. Time course of mild arm lymphedema after breast conservation treatment for early-stage breast cancer. Int J Radiation Oncology Biol Phys. doi:10.​1016/​j.​ijrobp.​2009.​01.​024, 2009; Aug 1 [Epub ahead of print].
46.
Szuba A, Rockson SG. Lymphedema: anatomy, physiology and pathogenesis. Vasc Med. 1997;2:321–6.PubMed
47.
Brorson H, Ohlin K, Olsson G, Nilsson M. Adipose tissue dominates chronic arm lymphedema following breast cancer: an analysis using volume rendered CT images. Lymphat Res Biol. 2006;4:199–210.CrossRefPubMed
Metadata
Title
Predictive Factors of Response to Decongestive Therapy in Patients with Breast-Cancer-Related Lymphedema
Authors
Isabel Forner-Cordero, MD, PhD
José Muñoz-Langa, MD, PhD
Arturo Forner-Cordero, PhD
Juan M. DeMiguel-Jimeno, MD
Publication date
01-03-2010
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 3/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0778-9

Other articles of this Issue 3/2010

Annals of Surgical Oncology 3/2010 Go to the issue

Melanomas

Who Is to Blame for False-Negative Sentinel Node Biopsies in Melanoma?

Breast Oncology

Contralateral Prophylactic Mastectomy Overtreatment: Expectations from Personal Genomics for Tailored Breast Cancer Surgery

Breast Oncology

Micrometastatic Sentinel Lymph Node Disease: Do Patients Benefit or Suffer Harm from Axillary Lymph Node Dissection?

Breast Oncology

Author Reply: Contralateral Prophylactic Mastectomy Overtreatment: Expectations from Personal Genomics for Tailored Breast Cancer Surgery

Breast Oncology

Obesity and Angiolymphatic Invasion in Primary Breast Cancer

Bone and Soft Tissue Sarcomas

Added Value of Molecular Biological Analysis in Diagnosis and Clinical Management of Liposarcoma: A 30-Year Single-Institution Experience